Please assess the completion status of the following clinical trial:

Trial Title: An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years of age.~* Subjects who are experiencing 1-4 episodes of break through pain per day in spite of optimized background analgesia and who have taken at least 60 mg/day of morphine (or equivalent analgesic) for at least 7 days.~* Who are currently using Actiq® for their breakthrough pain and are being discontinued due to lack of efficacy, side effects, patient dissatisfaction or prescriber dissatisfaction with treatment.~* Are able to follow and complete all necessary study procedures.~* Are willing and able to give written informed consent before participating in the study.~* Enrolled in the class wide REMS as verified by the study personnel.~Exclusion Criteria:~* Subjects who are not opioid tolerant.~* Using a rapid onset opioid other than Actiq® to manage their breakthrough pain.~* Have physical abnormalities of the floor of the mouth that could affect absorption as determined by investigator.~* Are subjects with uncontrolled or rapidly escalating pain.~* Are subjects with a history of alcohol or substance abuse within the last 3 years.~* Have a clinically significant medical history (past or present) of any disease that would compromise the study or the well-being of the subject.~* Are subjects who have participated in another clinical trial with an analgesic within the last month.~* Are female subjects with a positive pregnancy test or who are currently lactating.~* Are subjects who are taking medications that are known inhibitors of the CYP3A4 isozyme, such as ketoconazole.~* Are subjects who have taken a monoamine inhibitor within 14 days before a dose of study medication.~* Opioid being used for chronic migraine or acute pain.~* Are subjects who are unsuitable for inclusion for any other reason, in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subsys (Type: None): Cancer patients experiencing breakthrough pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).